NEW YORK (GenomeWeb News) – RedPath Integrated Pathology today announced the execution of an agreement with preferred provider organization MultiPlan for RedPath's PathFinder TG test for pancreatic cancer.

The contract is the seventh inked by the Pittsburgh-based molecular diagnostics firm with a national PPO and expands the number of covered lives for the test to more than 74 million people, RedPath said. PathFinder TG produces mutational profiles to help physicians "resolve complex diagnostic dilemmas in patients who are at risk of cancer."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.